|
Avaliação Sino Biopharmaceutical Limited (1177.HK) DCF
HK | Healthcare | Biotechnology | HKSE
|
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Sino Biopharmaceutical Limited (1177.HK) Bundle
Explore o futuro financeiro da Sino Biopharmaceutical Limited (1177HK) com nossa calculadora DCF amigável! Digite suas suposições sobre crescimento, margens e custos para calcular o valor intrínseco da Sinopharmaceutical Limited (1177HK) e aprimorar sua estratégia de investimento.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25,878.6 | 25,252.0 | 28,684.2 | 30,733.5 | 27,977.4 | 28,631.1 | 29,300.2 | 29,984.8 | 30,685.5 | 31,402.5 |
| Revenue Growth, % | 0 | -2.42 | 13.59 | 7.14 | -8.97 | 2.34 | 2.34 | 2.34 | 2.34 | 2.34 |
| EBITDA | 7,866.0 | 6,987.3 | 21,222.5 | 7,145.4 | 7,453.1 | 10,418.4 | 10,661.9 | 10,911.0 | 11,166.0 | 11,426.9 |
| EBITDA, % | 30.4 | 27.67 | 73.99 | 23.25 | 26.64 | 36.39 | 36.39 | 36.39 | 36.39 | 36.39 |
| Depreciation | 1,565.5 | 1,767.1 | 1,059.9 | 1,118.0 | 1,147.2 | 1,401.8 | 1,434.6 | 1,468.1 | 1,502.4 | 1,537.5 |
| Depreciation, % | 6.05 | 7 | 3.7 | 3.64 | 4.1 | 4.9 | 4.9 | 4.9 | 4.9 | 4.9 |
| EBIT | 6,300.5 | 5,220.1 | 20,162.6 | 6,027.4 | 6,305.9 | 9,016.6 | 9,227.3 | 9,442.9 | 9,663.6 | 9,889.4 |
| EBIT, % | 24.35 | 20.67 | 70.29 | 19.61 | 22.54 | 31.49 | 31.49 | 31.49 | 31.49 | 31.49 |
| Total Cash | 20,402.1 | 17,546.9 | 16,865.9 | 18,070.0 | 15,076.3 | 18,312.8 | 18,740.8 | 19,178.7 | 19,626.9 | 20,085.5 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 2,896.3 | 3,111.8 | 4,576.0 | 4,958.6 | 4,908.1 | 4,188.5 | 4,286.3 | 4,386.5 | 4,489.0 | 4,593.9 |
| Account Receivables, % | 11.19 | 12.32 | 15.95 | 16.13 | 17.54 | 14.63 | 14.63 | 14.63 | 14.63 | 14.63 |
| Inventories | 1,771.2 | 2,007.6 | 2,069.2 | 2,486.9 | 2,128.8 | 2,159.3 | 2,209.8 | 2,261.4 | 2,314.2 | 2,368.3 |
| Inventories, % | 6.84 | 7.95 | 7.21 | 8.09 | 7.61 | 7.54 | 7.54 | 7.54 | 7.54 | 7.54 |
| Accounts Payable | 1,932.2 | 2,080.0 | 1,916.5 | 2,011.6 | 1,425.3 | 1,948.3 | 1,993.9 | 2,040.4 | 2,088.1 | 2,136.9 |
| Accounts Payable, % | 7.47 | 8.24 | 6.68 | 6.55 | 5.09 | 6.8 | 6.8 | 6.8 | 6.8 | 6.8 |
| Capital Expenditure | -1,851.6 | -1,985.3 | -2,022.5 | -1,821.4 | -1,819.3 | -1,975.4 | -2,021.5 | -2,068.8 | -2,117.1 | -2,166.6 |
| Capital Expenditure, % | -7.16 | -7.86 | -7.05 | -5.93 | -6.5 | -6.9 | -6.9 | -6.9 | -6.9 | -6.9 |
| Tax Rate, % | 56.9 | 56.9 | 56.9 | 56.9 | 56.9 | 56.9 | 56.9 | 56.9 | 56.9 | 56.9 |
| EBITAT | 5,296.9 | 4,520.0 | 15,859.0 | 5,218.0 | 2,718.1 | 6,834.4 | 6,994.1 | 7,157.5 | 7,324.8 | 7,496.0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | 2,275.6 | 3,997.5 | 13,207.1 | 3,809.7 | 1,868.2 | 7,473.0 | 6,304.3 | 6,451.7 | 6,602.4 | 6,756.7 |
| WACC, % | 6.37 | 6.39 | 6.33 | 6.39 | 6.07 | 6.31 | 6.31 | 6.31 | 6.31 | 6.31 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 28,123.1 | |||||||||
| Long Term Growth Rate, % | 1.00 | |||||||||
| Free cash flow (T + 1) | 6,824 | |||||||||
| Terminal Value | 128,549 | |||||||||
| Present Terminal Value | 94,673 | |||||||||
| Enterprise Value | 122,796 | |||||||||
| Net Debt | 3,341 | |||||||||
| Equity Value | 119,455 | |||||||||
| Diluted Shares Outstanding, MM | 18,529 | |||||||||
| Equity Value Per Share | 6.45 |
Benefits of Choosing Us
- Authentic 1177HK Financial Data: Comes pre-loaded with Sino Biopharmaceutical Limited’s historical and forecasted financials for accurate analysis.
- Completely Customizable Template: Easily adjust essential parameters such as revenue growth, WACC, and EBITDA percentages.
- Instant Calculations: Watch the intrinsic value of 1177HK update in real-time as you make changes.
- Professional Valuation Resource: Tailored for investors, analysts, and consultants who require reliable DCF results.
- Intuitive User Interface: Designed for simplicity with clear guidance suitable for users of all skill levels.
Key Features
- Accurate Sino Biopharmaceutical Limited Financials: Gain access to precise pre-loaded historical data and future forecasts for (1177HK).
- Adjustable Forecast Parameters: Modify highlighted cells such as WACC, growth rates, and profit margins to suit your analysis.
- Real-Time Calculations: Automatic updates to DCF, Net Present Value (NPV), and cash flow assessments for (1177HK).
- User-Friendly Dashboard: Clear charts and summaries that help visualize your valuation outcomes effectively.
- Suitable for All Levels: An intuitive layout designed for investors, CFOs, and consultants, whether novice or expert.
How It Works
- Step 1: Download the Excel file.
- Step 2: Examine Sino Biopharmaceutical Limited's (1177HK) pre-filled financial data and forecasts.
- Step 3: Adjust key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update in real-time as you modify your assumptions.
- Step 5: Evaluate the results and utilize the findings for your investment decisions.
Why Select This Calculator for Sino Biopharmaceutical Limited (1177HK)?
- User-Friendly and Intuitive: Crafted for both novices and seasoned experts.
- Customizable Inputs: Easily adjust parameters to accurately reflect your analysis.
- Real-Time Updates: Observe immediate changes to Sino Biopharmaceutical’s valuation as you modify inputs.
- Pre-Configured: Comes loaded with Sino Biopharmaceutical’s actual financial data for swift evaluations.
- Preferred by Professionals: Utilized by investors and analysts to make well-informed decisions.
Who Should Use This Product?
- Finance Students: Discover valuation techniques and practice with real market data for Sino Biopharmaceutical Limited (1177HK).
- Academics: Integrate professional valuation models into your courses or research projects focused on Sino Biopharmaceutical Limited (1177HK).
- Investors: Evaluate your hypotheses and analyze valuation results specifically for Sino Biopharmaceutical Limited (1177HK).
- Analysts: Enhance your efficiency with a customizable DCF model designed for Sino Biopharmaceutical Limited (1177HK).
- Small Business Owners: Learn valuable insights from the analysis of large public firms like Sino Biopharmaceutical Limited (1177HK).
Contents of the Template
- All-Inclusive DCF Model: Editable template featuring thorough valuation computations.
- Real-World Data: Sino Biopharmaceutical Limited’s (1177HK) historical and forecasted financials preloaded for comprehensive analysis.
- Customizable Inputs: Modify WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for more profound insights.
- Key Financial Ratios: Integrated analysis covering profitability, efficiency, and leverage metrics.
- Dashboard with Visual Representations: Charts and tables providing clear and actionable results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.